RxDoctor Payments Data

Ran Schwarzkopf

Orthopedic Surgery · Orange, CANPI 1407016488

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (30.9%), royalties or licence payments and speaking fees — rather than concentrated in one kind of arrangement. Smith+Nephew accounts for 92.3% of it on its own, with 13 other manufacturers making up the rest. Among orthopedic surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,036,695in general payments, 2019–2025

Across 907 payments — averaging $2245.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$1.9M
  • Zimmer Biomet$78K
  • Stryker$36K
  • Intellijoint Surgical Inc.$22K
  • Microport Orthopedics Inc$7K
  • Pacira Pharmaceuticals Incorporated$5K
  • plus $9K from 8 others
$3,324,524in research payments, 2019–2025

Across 338 payments — averaging $9835.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Smith+Nephew$3.2M
  • Johnson & Johnson$82K
$88,008in ownership & investment interests, 2019–2025

Across 13 payments — averaging $6769.87 each. An ownership or investment interest held by the physician or an immediate family member.

  • Intellijoint Surgical Inc.$88K

What the payments were for

  • Royalty or licence$629,24731%
  • Consulting fees$629,37331%
  • Speaking & faculty fees$582,51029%
  • Travel & lodging$134,2927%
  • Food & beverage$26,1811%
  • Other$35,0912%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,036,695 in reported general payments places this provider in the 95th percentile of 130 orthopedic surgery providers in California.

See all orthopedic surgery providers in California

Medicare billing

Part B allowed, 2024
$585,396
Medicare patients
785
Services billed
3,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam224$611
Gabapentin12$81
Tramadol Hcl12$39
Amoxicillin16$20

Paid to pharmacies, not to this prescriber.

Other orthopedic surgery in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →